Title:
COMBINED USE OF CTB006 AND PONATINIB
Document Type and Number:
WIPO Patent Application WO/2021/175326
Kind Code:
A1
Abstract:
Provided herein is an anti-tumor drug combination, comprising a TRAIL-R2 agonistic antibody (such as CTB006) and Ponatinib or a hydrochloride salt thereof. Also provided herein is a tumor treatment method, comprising administering to a patient a therapeutically effective amount of the TRAIL-R2 agonist antibody and Ponatinib or a hydrochloride salt thereof. Synergy of the two helps to enhance therapeutic effects of tumors.
Inventors:
ZHONG XIAOYAN (CN)
CAO FENGQI (CN)
LI ZHE (CN)
CAO FENGQI (CN)
LI ZHE (CN)
Application Number:
PCT/CN2021/079403
Publication Date:
September 10, 2021
Filing Date:
March 05, 2021
Export Citation:
Assignee:
BEIJING SINOTAU BIO PHARMACEUTICALS TECH CO LTD (CN)
International Classes:
A61K39/395; A61K31/5025; A61K38/21; A61P35/00; C07K16/28
Domestic Patent References:
| WO2016074245A1 | 2016-05-19 |
Foreign References:
| CN108472359A | 2018-08-31 | |||
| CN109875999A | 2019-06-14 | |||
| CN107108736A | 2017-08-29 | |||
| CN2007001453W | 2007-04-29 |
Other References:
TANG XIU-HONGQIN SHU-KUICHEN HUI-YING ET AL.: "Increasing anti-tumor effect of arsenic trioxide combining with cisplatin on the QGY-7701 human hepatocarcinoma cells line", CANCER RESEARCH ON PREVENTION AND TREATMENT, vol. 29, 2002, pages 362 - 364
ZHIYONG LIAOSHENGHUA ZHANGYONGSU ZHEN: "Geldanamycin enhances antitumor efficacy of cisplatin", CHINESE JOURNAL OF CANCER, vol. 19, no. 8, 2000, pages 731 - 734
See also references of EP 4115902A4
ZHIYONG LIAOSHENGHUA ZHANGYONGSU ZHEN: "Geldanamycin enhances antitumor efficacy of cisplatin", CHINESE JOURNAL OF CANCER, vol. 19, no. 8, 2000, pages 731 - 734
See also references of EP 4115902A4
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF:
Previous Patent: BUCCAL TUBE HAVING MOVABLE TRACTION MEMBER
Next Patent: DEVICE AND METHOD FOR QUITTING SMOKING
Next Patent: DEVICE AND METHOD FOR QUITTING SMOKING